ANIP - ANI Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
52.07
-0.83 (-1.57%)
As of 1:05PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close52.90
Open52.89
Bid52.43 x 900
Ask52.71 x 800
Day's Range51.89 - 53.89
52 Week Range36.92 - 72.81
Volume13,797
Avg. Volume78,949
Market Cap616.858M
Beta (3Y Monthly)1.89
PE Ratio (TTM)1,531.47
EPS (TTM)0.03
Earnings DateNov 1, 2017 - Nov 6, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est70.33
Trade prices are not sourced from all markets
  • How Much is ANI Pharmaceuticals, Inc.’s (NASDAQ:ANIP) CEO Getting Paid?
    Simply Wall St.14 days ago

    How Much is ANI Pharmaceuticals, Inc.’s (NASDAQ:ANIP) CEO Getting Paid?

    In 2013 Arthur Przybyl was appointed CEO of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar Read More...

  • 3 Under-the-Radar Value Stocks to Buy in 2019
    Motley Fool22 days ago

    3 Under-the-Radar Value Stocks to Buy in 2019

    These might be the cheapest stocks you've never heard about.

  • PR Newswire27 days ago

    ANI Pharmaceuticals Secures Refinancing for Convertible Debt Due December 2019 and Enters Amended Five-Year $265 Million Senior Secured Credit Facility

    BAUDETTE, Minn., Dec. 27, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (ANIP) today announced that it has entered an amended and restated five-year Senior Secured Credit Facility (the "Facility") for up to $265.2 million with its existing syndicate of bank lenders (the "Bank Group"). The Facility amends ANI's current $125 million Senior Secured Credit Facility and is structured to provide ANI flexibility in refinancing its 3.00% Convertible Senior Notes due 2019 ("the Convertible Notes"). The principal feature of the Facility is a new $118.0 million Delayed Draw Term Loan available to refinance ANI's Convertible Notes maturing in December 2019.

  • Hedge Funds Are Crazy About ANI Pharmaceuticals Inc (ANIP)
    Insider Monkeylast month

    Hedge Funds Are Crazy About ANI Pharmaceuticals Inc (ANIP)

    Legendary investors such as Leon Cooperman and Seth Klarman earn enormous amounts of money for themselves and their investors by doing in-depth research on small-cap stocks that big brokerage houses don’t publish. Small cap stocks -especially when they are screened well- can generate substantial outperformance versus a boring index fund. That’s why we analyze the […]

  • PR Newswire2 months ago

    ANI Pharmaceuticals Enters into Separate Privately Negotiated Agreements with Certain Holders of its Convertible Notes

    BAUDETTE, Minn., Dec. 7, 2018 /PRNewswire/ -- (ANIP) ANI Pharmaceuticals, Inc. (the "Company" or "ANI") today announced that it has entered into separate, privately negotiated agreements with certain holders of its outstanding 3.00% Convertible Senior Notes due 2019 (the "Notes"). ANI has agreed to repurchase $25.0 million aggregate principal amount of Notes for a total of $26.1 million in cash, including accrued but unpaid interest up to but excluding the closing date for the transactions. In connection with the contemplated repurchase of Notes, ANI has also entered into an agreement with the dealer party to certain convertible note hedge transactions related to the Notes to unwind a corresponding portion of such convertible note hedge transactions.

  • 3 Top Small-Cap Stocks to Buy Right Now
    Motley Fool2 months ago

    3 Top Small-Cap Stocks to Buy Right Now

    These stocks may be small in stature, but they're big on growth potential.

  • What You Must Know About ANI Pharmaceuticals Inc’s (NASDAQ:ANIP) Financial Strength
    Simply Wall St.2 months ago

    What You Must Know About ANI Pharmaceuticals Inc’s (NASDAQ:ANIP) Financial Strength

    While small-cap stocks, such as ANI Pharmaceuticals Inc (NASDAQ:ANIP) with its market cap of US$655m, are popular for their explosive growth, investors should also be aware of their balance sheet Read More...

  • Is ANI Pharmaceuticals a Great Stock for Value Investors?
    Zacks2 months ago

    Is ANI Pharmaceuticals a Great Stock for Value Investors?

    Let???s see if ANI Pharmaceuticals (ANIP) stock is a good choice for value-oriented investors right now from multiple angles.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ANIP earnings conference call or presentation 6-Nov-18 3:30pm GMT

    Q3 2018 ANI Pharmaceuticals Inc Earnings Call

  • PR Newswire2 months ago

    ANI Pharmaceuticals, Inc. Ranked Number 366 Fastest Growing Company in North America on Deloitte's 2018 Technology Fast 500™

    BAUDETTE, Minn., Nov. 15, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (ANIP) today announced it ranked No. 366 on Deloitte's Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America. ANI revenue grew 216% during this period. ANI's President and CEO, Arthur S. Przybyl, said, "I want to thank our employees for their hard work and contributions, which have enabled ANI to be listed on Deloitte's Technology Fast 500™ for the second year in a row.

  • GlobeNewswire2 months ago

    Research Report Identifies Canopy Growth, MSG Networks, ANI Pharmaceuticals, Mistras Group, Rowan Companies, and Chemours with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Nov. 12, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • ANI Pharmaceuticals Inc (ANIP) Q3 2018 Earnings Conference Call Transcript
    Motley Fool3 months ago

    ANI Pharmaceuticals Inc (ANIP) Q3 2018 Earnings Conference Call Transcript

    ANIP earnings call for the period ending September 30, 2018.

  • ANI Pharmaceuticals (ANIP) Q3 Earnings and Revenues Surpass Estimates
    Zacks3 months ago

    ANI Pharmaceuticals (ANIP) Q3 Earnings and Revenues Surpass Estimates

    ANI (ANIP) delivered earnings and revenue surprises of 5.74% and 0.20%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press3 months ago

    ANI: 3Q Earnings Snapshot

    The Baudette, Minnesota-based company said it had profit of 42 cents per share. Earnings, adjusted for one-time gains and costs, came to $1.29 per share. The drugmaker posted revenue of $50.7 million in ...

  • PR Newswire3 months ago

    ANI Pharmaceuticals Reports Third Quarter and Year-To-Date 2018 Results and Reaffirms Guidance

    BAUDETTE, Minn. , Nov. 6, 2018 /PRNewswire/ -- For the third quarter 2018: Record net revenues of $50.7 million , an increase of 5% as compared to the same period in 2017 GAAP net income of $5.0 million ...

  • PR Newswire3 months ago

    ANI Pharmaceuticals Schedules Conference Call to Discuss Third Quarter and Year-to-Date 2018 Financial Results

    BAUDETTE, Minn. , Oct. 30, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its third quarter and year-to-date 2018 financial results on Tuesday, ...

  • PR Newswire3 months ago

    ANI Announces Launch of Authorized Generic of Brethine®

    BAUDETTE, Minn., Oct. 16, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (ANIP) today announced the launch of Terbutaline Sulfate Tablets USP, 2.5mg and 5mg, an authorized generic of Brethine®. The current annual U.S. market for this product is approximately $11 million, according to Iqvia. Prior to ANI's launch there was only one supplier of the product in the U.S. market. ANI acquired the NDA for Brethine® (terbutaline sulfate) tablets in December 2016. Arthur S. Przybyl, ANI's President and CEO stated, "ANI continues to successfully execute on our strategy of re-commercializing products from our portfolio of acquired discontinued ANDAs and NDAs.

  • PR Newswire4 months ago

    ANI Pharmaceuticals Announces Launch of Authorized Generic of Atacand HCT® Tablets

    BAUDETTE, Minn., Oct. 4, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (ANIP) today announced the launch of Candesartan Hydrochlorothiazide Tablets, 16mg/12.5mg, 32mg/12.5mg, and 32mg/25mg, an authorized generic of Atacand HCT®.  The current annual U.S. market for this product is approximately $20 million, according to Iqvia/IMS Health. Arthur S. Przybyl, ANI's President and CEO stated, "We are pleased to announce the launch of the authorized generic of our brand product Atacand HCT®. Atacand HCT® is indicated for the treatment of hypertension.

  • PR Newswire4 months ago

    ANI Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference

    BAUDETTE, Minn., Sept. 27, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (ANIP) announced today that it will present on Wednesday, October 3, 2018 at 2:50 PM ET at the Cantor Fitzgerald Global Healthcare Conference in New York City. Arthur S. Przybyl, President and CEO and Stephen P. Carey, Vice President, Finance and CFO, will present on behalf of ANI Pharmaceuticals, Inc. The presentation will be webcast live at http://wsw.com/webcast/cantor7/anip/ and will be archived and available through the link through January 1, 2019. ANI Pharmaceuticals, Inc. (the "Company" or "ANI") is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals.

  • ANI Pharmaceuticals Inc (NASDAQ:ANIP) Is Trading At A 47.84% Discount
    Simply Wall St.4 months ago

    ANI Pharmaceuticals Inc (NASDAQ:ANIP) Is Trading At A 47.84% Discount

    In this article I am going to calculate the intrinsic value of ANI Pharmaceuticals Inc (NASDAQ:ANIP) by estimating the company’s future cash flows and discounting them to their present value.Read More...

  • New Product Launches to Drive Ani Pharmaceuticals’ 2018 Revenue
    Market Realist4 months ago

    New Product Launches to Drive Ani Pharmaceuticals’ 2018 Revenue

    Ani Pharmaceuticals (ANIP) is a specialty pharmaceutical company with 29 commercial products in its generic Rx portfolio and 11 commercial products in its branded Rx portfolio. Ani Pharmaceuticals has reported a return of -17.84% YTD (year-to-date) in 2018. Analysts’ 12-month consensus recommendation for Ani Pharmaceuticals as of September 23 is a “strong buy.” The 12-month consensus target price for Ani Pharmaceuticals is $72.00, which is 35.98% higher than its closing price on September 21.

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of ANIP earnings conference call or presentation 7-Aug-18 2:30pm GMT

    Q2 2018 ANI Pharmaceuticals Inc Earnings Call

  • PR Newswire6 months ago

    ANI Pharmaceuticals to Present at New Time at the Canaccord Genuity 38th Annual Growth Conference

    Arthur S. Przybyl, President and CEO and Stephen P. Carey, Vice President, Finance and CFO, will present on behalf of ANI Pharmaceuticals, Inc. The presentation will be webcast live at http://wsw.com/webcast/canaccord30/anip/ and will be archived and available through the link through November 7, 2018. ANI Pharmaceuticals, Inc. (the "Company" or "ANI") is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals.